What We're Reading: Page 310
Industry reads hand-picked by our editors
Oct 19, 2016
-
Xconomy
After 'hubris' and its HCV collapse, can Vertex avoid same mistakes?
-
MIT Technology Review
Gene therapy in U.S. is on track for approval as early as next year
-
BloombergGadfly
Biotech shouldn't sweat the election so much
Oct 18, 2016
-
EP Vantage
M&A gives signs of reverting to the mean
-
Bloomberg
Bayer's euphoria around new cancer medicine meets skepticism
-
Healthcare Dive
Omnicare to pay $28M over alleged kickbacks from Abbott
-
Boston Globe
Veritas Genetics draws $30 million in funding
Oct 17, 2016
-
MIT Technology Review
Can CRISPR Save Ben Dupree?
-
Bloomberg
Gels to repair hearing loss? Drugmakers try new ear treatments
-
The Street
Celgene Crohn's pill data unspectacular but perhaps good enough
-
Journal Sentinel
With overactive bladder, drug companies helped create $3 billion market
Oct 14, 2016
Oct 13, 2016
-
Nature
Safety concerns blight promising cancer therapy
-
Bloomberg
The man behind India's best stock faces his biggest test
-
Boston Business Journal
​R&D spending takes a back seat to other costs at Boston’s biggest biotechs
-
New York Times
Drug coupons: Helping a few at the expense of everyone
Oct 12, 2016
Oct 11, 2016
-
BloombergGadfly
Bristol's failure of leadership
-
The New York Times
Theranos sued by investor who accuses it of securities fraud
-
The San Diego Union-Tribune
Illumina plummets on lowered revenue guidance
-
The Street
Even high-flying Tesaro and its ovarian cancer drug has a bear thesis
-
Reuters
Doctors grapple with best use of potent new cancer drugs
Previous
